In January 1999, Cytomed Inc was acquired by UCB Pharma Inc -- a wholly-owned subsidiary of LeukoSite, Inc. (Nasdaq: LKST),. A venture funded biopharmaceutical company committed to the discovery and development of novel proprietary products for the treatment of inflammatory diseases. Cytomed began a combination Phase I/II trial in the United States with CMI392, a potential treatment for psoriasis and a form of dermatitis Cytomed also had negotiating with a corporate partner for the asthma drug. The company signed a deal Steifel Laboratories, giving the Florida company marketing rights in Europe, Canada and Latin America. Cytomed retained rights for U.S. sales.
